Multivariable Cox regression analysis for PFS in previously treated CLL patients including predicted partial vs complete TP53 disruption according to the TP53 mutation/deletion status (n = 446)
| Variable . | Comparison (no. of patients) . | HR (95%CI) . | P* . |
|---|---|---|---|
| RND | FC vs FCR | 0.60 (0.48-0.76) | <.001 |
| Binet stage | A/B vs C | 1.68 (1.32-2.14) | <.001 |
| Age | Continuous | 1.01 (1.00-1.02) | .110 |
| IGVH | Mutated vs unmutated | 2.47 (1.90-3.21) | <.001 |
| Heterozygous TP53mut (subgroup 2) | No vs yes (16) | 1.61 (0.94-2.77) | .084 |
| Hemizygous del17p (subgroup 3) | No vs yes (9) | 2.21 (1.13-4.33) | .021 |
| TP53mut/del 17p (subgroup 4) | No vs yes (28) | 2.79 (1.83-4.24) | <.001 |
| TP53DN or > 1TP53mut (subgroup 5) | No vs yes (8) | 3.26 (1.49-7.12) | .003 |
| Variable . | Comparison (no. of patients) . | HR (95%CI) . | P* . |
|---|---|---|---|
| RND | FC vs FCR | 0.60 (0.48-0.76) | <.001 |
| Binet stage | A/B vs C | 1.68 (1.32-2.14) | <.001 |
| Age | Continuous | 1.01 (1.00-1.02) | .110 |
| IGVH | Mutated vs unmutated | 2.47 (1.90-3.21) | <.001 |
| Heterozygous TP53mut (subgroup 2) | No vs yes (16) | 1.61 (0.94-2.77) | .084 |
| Hemizygous del17p (subgroup 3) | No vs yes (9) | 2.21 (1.13-4.33) | .021 |
| TP53mut/del 17p (subgroup 4) | No vs yes (28) | 2.79 (1.83-4.24) | <.001 |
| TP53DN or > 1TP53mut (subgroup 5) | No vs yes (8) | 3.26 (1.49-7.12) | .003 |
P values were calculated using the Wald test.